GRIA1 and neurodegenerative disease: By administering these compounds to GluA1, GluA1/2, GluA2, and GluA3 AMPARs, we hope to obtain further insight into their mechanism and aid in the pursuit of discovering effective therapeutic compounds for a multitude of neurodegenerative diseases.